Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | WIZ | O95785 | 3/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.39 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.39 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | BCL6 | P41182 | 1/20 | 0.36 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31595670 | 0.80 | BCL6 (0.46) | MAPTCRBNDDB1BCL6BCOR | |
| SCHEMBL23249931 | 0.77 | CRBN (0.38) | CRBNIKZF2GSPT1DDB1BCL6 | |
| SCHEMBL23249934 | 0.77 | CRBN (0.38) | CRBNIKZF2GSPT1DDB1BCL6 | |
| SCHEMBL31595273 | 0.76 | BCL6 (0.43) | CRBNGSPT1DDB1BCL6BCOR | |
| SCHEMBL23249988 | 0.76 | CRBN (0.37) | CRBNIKZF2GSPT1DDB1BCL6 | |
| SCHEMBL31595469 | 0.75 | CRBN (0.50) | CRBNDDB1 | |
| SCHEMBL34466813 | 0.73 | CRBN (0.47) | MAPTWIZCRBNIKZF2GSPT1 | |
| SCHEMBL34466550 | 0.73 | CRBN (0.47) | MAPTWIZCRBNIKZF2GSPT1 | |
| SCHEMBL23968543 | 0.72 | CRBN (0.51) | MAPTWIZCRBNIKZF2 | |
| SCHEMBL23249944 | 0.72 | BCL6 (0.39) | MAPTBCL6BCOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | MAPT 2421/4885WIZ 1072/4885CRBN 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.